[Ischemic cholangitis in intensive care unit: favourable outcome with ursodesoxycholic acid and fenofibrate]

Rev Med Interne. 2013 Feb;34(2):110-3. doi: 10.1016/j.revmed.2012.10.376. Epub 2012 Nov 30.
[Article in French]

Abstract

Introduction: Ischemic cholangitis in intensive care unit is a recently reported liver disease in patients who have had a prolonged mechanical ventilation and vasopressive drug support for multiple organ deficiency. Prognosis is usually poor and the only life-saving therapy is liver transplantation despite ursodesoxycholic acid treatment.

Case report: We report a 63-year-old man who presented with a sclerosis cholangitis after a month in intensive care unit, effectively treated with fenofibrate and ursodesoxycholic acid. Recent reports underline fenofibrate efficacy in the treatment of primary biliary cirrhosis, especially in association with ursodesoxycholic acid. This treatment has prevented liver transplantation for our patient with a correct quality of life.

Conclusion: The addition of fibrate to ursodesoxycholic acid improves persistent cholestasis in sclerosing cholangitis.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Cholagogues and Choleretics / administration & dosage
  • Cholagogues and Choleretics / therapeutic use
  • Cholangitis, Sclerosing / drug therapy*
  • Cholangitis, Sclerosing / etiology*
  • Critical Care*
  • Fenofibrate / administration & dosage*
  • Fenofibrate / therapeutic use
  • Humans
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / therapeutic use
  • Intensive Care Units
  • Male
  • Middle Aged
  • Treatment Outcome
  • Ursodeoxycholic Acid / administration & dosage*
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • Cholagogues and Choleretics
  • Hypolipidemic Agents
  • Ursodeoxycholic Acid
  • Fenofibrate